Last updated on February 2019

Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

Brief description of study

The purpose of this study is to provide access to palbociclib in Mexico and in selected Latin American countries before it becomes commercially available to patients with HR positive/HER2-negative ABC who are appropriate candidates for letrozole therapy.

Clinical Study Identifier: NCT02600923

Contact Investigators or Research Sites near you

Start Over

Pfizer Call Center

Fucam A.C.
Coyoacan, Mexico

Pfizer Call Center

Instituto Nacional de Cancerologia
Tlalpan, Mexico

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.